SCHEMBL19974901

SCHEMBL19974901

COc1cccc(Cl)c1N(C=O)C(C)C(=O)C(=O)NCC1CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.38
MAPT P10636 1/20 0.37
ALDH1A1 P00352 2/20 0.37
GAA P10253 2/20 0.37
LMNA P02545 1/20 0.37
TSHR P16473 1/20 0.37
DRD2 P14416 2/20 0.36
TP53 P04637 1/20 0.36
ALPL P05186 1/20 0.36
ALPI P09923 1/20 0.36
ALPG P10696 1/20 0.36
CNR2 P34972 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
VCP P55072 1/20 0.35
PTGIR P43119 1/20 0.35
ADRA1A P35348 1/20 0.35
ADRA1B P35368 1/20 0.35
HTR4 Q13639 3/20 0.34
POLB P06746 1/20 0.34
TAS1R3 Q7RTX0 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19974845 0.91 DRD2 (0.40) ALDH1A1GAADRD2TP53CNR2
SCHEMBL19975130 0.83 HPGD (0.42) HPGDMAPTALDH1A1GAALMNA
SCHEMBL19975296 0.83 ALDH1A1 (0.38) HPGDMAPTALDH1A1GAALMNA
SCHEMBL19974871 0.81 MEN1 (0.39) ALDH1A1GAADRD2TP53CNR2
SCHEMBL19975377 0.79 HPGD (0.50) HPGDMAPTALDH1A1GAALMNA
SCHEMBL19975081 0.77 CTSD (0.41) HPGDMAPTLMNATP53CNR2
SCHEMBL19975567 0.77 ALDH1A1 (0.46) MAPTALDH1A1GAACNR2L3MBTL1
SCHEMBL21176277 0.76 PTGIR (0.41) PTGIR
SCHEMBL19974903 0.74 ITGB1 (0.40) HPGDMAPTDRD2TP53ALPL
SCHEMBL19975512 0.74 PTGIR (0.40) ALDH1A1PTGIRPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220356148-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2022-11-10 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
EP-3512836-A1 ANTIVIRAL COMPOUNDS Haplogen GmbH (AT) 2019-07-24 EP disclosed
WO-2018050631-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225575-A1 ANTIVIRAL COMPOUNDS PLA2G1B, PLA2G12A, PLA2G4C HPGD 1205/4885MAPT 4561/4885ALDH1A1 2271/4885
US-20220356148-A1 ANTIVIRAL COMPOUNDS PLA2G12A, PLA2G1B, PLA2G4C HPGD 1156/4885MAPT 4673/4885ALDH1A1 2673/4885
US-11091428-B2 Antiviral compounds PLA2G1B, PLA2G12A, PLA2G4C HPGD 1205/4885MAPT 4561/4885ALDH1A1 2271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.